Erythromycin before endoscopy improves visualization of the gastric mucosa.

Published Date: 06 Mar 2023

A new study by Diego Adão and team has shown that using erythromycin before the exam can improve your ability to see your vision.

Read Full News

Latest News

Unraveling the Complexities of Concomitant IBD and Hepatobiliary Disease, With Natalia Nedelkopoulou, MD Natalia Nedelkopoulou, MD

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Navigating Autoimmune Overlap in Celiac Disease, With Daniel Mallon, MD Daniel Mallon, MD

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Latest News

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

News All Time

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Gastroenterology in 2025: Year in Review

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

New research demonstrates a method for screening people at high risk for pancreatic cancer.

Obesity-associated cancers may be on the rise in Puerto Rico

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Breast density changes over time are associated with an increased risk of cancer.

3.

Best foot forward—chemo care should include podiatry, say researchers

4.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

5.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

1.

Unlocking Immunity: TILs, Immunotherapy Biomarkers, and Toxicity Management in Oncology

2.

Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction

3.

Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms

4.

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology

5.

Unlocking the Potential of Polatuzumab for Cancer Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I

4.

Navigating the Complexities of Ph Negative ALL - Part X

5.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Erythromycin before endoscopy improves visualization of the gastric mucosa.

Latest News

Unraveling the Complexities of Concomitant IBD and Hepatobiliary Disease, With Natalia Nedelkopoulou, MD Natalia Nedelkopoulou, MD

Navigating Autoimmune Overlap in Celiac Disease, With Daniel Mallon, MD Daniel Mallon, MD

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

Latest News

News All Time

Young Adults With IBD Face Greater Healthcare Access Challenges, Financial Burdens

Gastroenterology in 2025: Year in Review

Young Women With Ulcerative Colitis Face Higher Corticosteroid Exposure Risk

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

Recommended News For You

Traveling to Die: The Latest Form of Medical Tourism

Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.

Modified personalized cancer vaccine generates powerful immune response

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

An individual state lost $4.02 billion due to untreated mental illness.

New research demonstrates a method for screening people at high risk for pancreatic cancer.

Obesity-associated cancers may be on the rise in Puerto Rico

Recommended Articles For You

Immunotherapy Breakthroughs: Transforming Cancer Care Across All Oncology Fields

Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

The Revolutionary Treatment of Hodgkin's Lymphoma: A New Hope for the Future

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.